Obama's Coming Stem-Cell Decision May Not Jump-Start Research
By Paul Basken,
Chronicle of Higher Education
| 02. 05. 2009
Eight years ago, President George W. Bush sharply limited federal support for stem-cell research. The move cost universities millions of dollars while slowing the hunt for life-saving medical advances. And it may now be only days before President Obama reverses course.
But for all the trouble the presidential restriction has caused, and for all the political trauma that may accompany a cancellation of Mr. Bush's order, both the science and the economics have evolved so far since 2001 that universities may feel affected far less by Mr. Obama's decision than they were by Mr. Bush's. Still, an obscure piece of legislation called the Dickey-Wicker Amendment may remain an obstacle no matter what the president does.
Mr. Obama's anticipated reversal of policy "won't be a boon the way some people might think," said Arnold R. Kriegstein, director of the Eli and Edythe Broad Center of Regeneration Medicine and Stem Cell Research at the University of California at San Francisco. "Time has moved on, and so has the field."
Stem cells are capable of growing into any type of cell of the...
Related Articles
By Emma McDonald Kennedy
| 10.29.2026
At the beginning of Nathan Fielder and Lance Oppenheim’s blockbuster documentary You Can See Everything, Billy Evans (partner of Theranos founder and convicted fraudster Elizabeth Holmes), says that they decided to do the film for one purpose: “radical transparency.” As they work on “Theranos 2.0,” Evans and Holmes want to show the public that she has been misunderstood –– painted as a liar and a fraud in the public imagination (and the courts) despite, as she claims in the...
By Charles Schmidt, Undark | 09.25.2026
In 2010, scientists at the University of Tokyo and other institutions reported a startling achievement: They had successfully grown a pancreas made almost entirely of rat cells within the bodies of mice. The research was directed by Hiromitsu Nakauchi, a...
By Editors, Nature | 08.18.2026
Shinya Yamanaka doesn’t see himself as a celebrity. But people do recognize the stem-cell researcher when he’s out for a run, often while training for a marathon, on the streets of Kyoto, Japan.
Many of them call out words of...
By Jessica Hamzelou, MIT Technology Review | 07.30.2026
As of this week in Montana, any biotech company with an experimental drug has a clear path to selling it to consumers. Companies whose drugs have been through preliminary testing—sometimes in as few as 10 healthy people—can pay $12,500 to...